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ABSTRACT 
Background: Biomarkers that identify individuals at risk of Alzheimer’s disease (AD) 
development would be highly valuable. Plasma concentration of amyloid  (A) – central in 
the pathogenesis of AD – is a logical candidate, but studies to date have produced conflicting 
results on its utility. 
Methods: Plasma samples from 339 preclinical AD cases (76.4% women, mean age 61.3 
years) and 339 age- and sex-matched dementia-free controls, taken an average of 9.4 years 
before AD diagnosis, were analyzed using Luminex xMAP technology and INNOBIA plasma 
A form assays to determine plasma concentrations of free A40 and A42. 
Results: Plasma concentrations of free A40 and A42 did not differ between preclinical AD 
cases and dementia-free controls, in the full sample or in sub-groups defined according to sex 
and age group (<60 and ≥60 years). The interval between sampling and AD diagnosis did not 
affect the results. A concentrations did not change in the years preceding AD diagnosis 
among individuals for whom longitudinal samples were available.  
Conclusion: Plasma concentrations of free A could not predict the development of clinical 
AD, and A concentrations did not change in the years preceding AD diagnosis in this 
sample. These results indicate that free plasma A is not a useful biomarker for the 
identification of individuals at risk of developing clinical AD. 
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 Research in context 
Systematic review 
The Pubmed database was searched using relevant keywords to identify previous research. 
Previous research suggested a possibly predictive value of plasma A measurement for the 
identification of individuals at risk of AD development, but results were conflicting. 
 
Interpretation 
Our results indicate that free plasma A cannot serve as a biomarker for the identification of 
individuals at risk of developing clinical AD. 
 
Future directions 
As free plasma A has a low predictive value, future research should seek to identify other 
plasma biomarkers for the risk of AD. 
 
Introduction 
Several possibly disease-modifying treatments for Alzheimer’s disease (AD) are currently 
being tested in phase 3 clinical trials. The identification of persons at risk of developing AD 
before symptom onset may thus soon become clinically relevant [1]. 
Amyloid pathology is present several years before the clinical onset of AD [2]. The analysis 
of peptide amyloid  (A) 1-42 in cerebrospinal fluid (CSF) has good diagnostic properties 
for AD in the clinical and prodromal disease stages, as has the measurements of amyloid 
burden with positron emission tomography (PET) [3, 4]. These two measures are highly 
concordant [4], and new AD criteria highlight their importance in directly reflecting amyloid 
pathology in AD [5]. However, neither CSF sampling through lumbar puncture nor amyloid 
PET investigation is feasible for screening to identify individuals at risk of developing AD in 
the general population. A blood test would be much practical in this context. 
Plasma A can be measured reliably using current assays, and given the firm relation between 
CSF A and AD pathology, it has been investigated as a possible biomarker for AD [6-10]. 
Findings, however, are conflicting. Results of some studies have indicated that lower A42 
concentrations or A42:A40 ratios are associated with a significantly increased risk of AD, 
whereas other studies have found the reverse relation or failed to identify any association [7-
10]. Funnel plots from a meta-analysis suggest the presence of publication bias toward studies 
showing a relationship between A42 and AD [7]. 
The aim of the present nested case-control study was to investigate the association between 
free plasma A and AD in a large sample of persons with preclinical AD and closely matched 
dementia-free controls, using plasma samples taken several years before AD diagnosis. 
Methods 
2.1 Participants 
This nested case-control study is part of the Consortium on Health and Ageing: Network of 
Cohorts in Europe and the United States (CHANCES) project [11]. Participants were selected 
using a computerized procedure. Individuals diagnosed with AD at the University Hospital 
Memory Clinic, Umeå, Sweden, for whom stored EDTA plasma samples collected before 
clinical disease onset were available in the Medical Biobank of Umeå (The Northern Sweden 
Health and Disease Study Cohort [12] were identified. Samples were selected when suitable 
age-, sex-, cohort- and sampling date-matched dementia-free controls could be identified. 
Specificera pre-analytics (är det EDTA plasma, hur togs proverna [på morgonen eller 
närsomhelst, fastande eller inte], hur centrifugerades och alikvoterades proverna?) 
 
2.2 Confirmation of AD diagnoses 
All AD cases had been examined and diagnosed at the University Hospital Memory Clinic in 
Umeå, Sweden. These diagnoses were the result of regular clinical investigations and were 
not related to participation in any study cohort. The diagnosis of AD was supported by typical 
symptoms of progressive cognitive failure; physical examination findings; results of cognitive 
screening tests, such as the Mini-Mental State Examination [13]; results of standard blood 
tests; and findings of examination using at least one brain imaging technique (x-ray computed 
tomography, magnetic resonance tomography, 99mTc single-photon emission computed 
tomography and/or fluorodeoxyglucose PET). In many cases, the diagnoses were further 
supported by findings from neuropsychological examination and CSF analysis. An 
experienced specialist in psychogeriatric medicine assessed the accuracy of AD diagnoses by 
thorough review of medical records before the final inclusion of cases in the data set. All AD 
cases were diagnosed according to the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSM-IV) criteria [14], and clinical diagnoses were also compatible 
with the National Institute of Neurological and Communicative Disorders and Stroke – 
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria [15].  
The dementia-free status of matched controls was checked using Swedish diagnosis registries, 
and persons were excluded when the diagnosis of any dementia disorder was found. The 
Swedish Death Registry was used to confirm that all controls were alive on the date of AD 
diagnosis for corresponding cases. 
 
2.3 Plasma analyses 
Plasma A40 and A42 concentrations were measured using Luminex xMAP technology and 
the INNOBIA plasma A forms assays (Innogenetics, Ghent, Belgium), as described 
previously [16]. As the measurements were performed on neat EDTA plasma without any 
pre-treatment, we measured the pool of A for which epitopes were available to the 
antibodies (free A). Plasma A concentrations are presented in nanograms per liter. The 
measurements were performed in one round of experiments using one batch of reagents by 
board-certified laboratory technicians who were blinded to clinical data.  
 
2.4 Statistical analysis 
Conditional logistic regression was used to test whether differences in A variables between 
AD cases and dementia-free controls were associated with AD, in the full sample and in the 
following sub-groups: men and women, participants aged ≥60 and <60 years at the time of 
plasma sampling, and quartiles defined according to the interval between sampling and AD 
diagnosis. Multiple linear regression was used to investigate the effects of age and sex on 
plasma A concentrations. A linear mixed model was used to analyze changes in A level 
between first sample collection and AD diagnosis among cases. P < 0.05 was considered to be 
statistically significant. SPSS software (version 22.0 for Macintosh; IBM Corporation, 
Armonk, NY, USA) was used for statistical calculations. 
Results 
The selection procedure resulted in the identification of 339 pairs of AD cases and dementia-
free controls (80 men and 259 women per group) that could be included in the present 
analysis. Matching was perfect with regard to sex and Medical Biobank sub-cohort. Samples 
from three Medical Biobank cohorts were included in the present study; the mammography 
screening cohort [n = 156 pairs (46.0%)], the Multinational MONItoring of trends and 
determinants in CArdiovascular disease (MONICA) project screening cohort [n = 3 pairs 
(0.9%)], and the Västerbotten Intervention Programme (VIP) cohort [n = 180 pairs (53.1%)] 
[12]. For some of the AD cases, additional plasma samples (n = 1, 89 persons; n = 2 , 45 
persons; n = 3, 13 persons; n ≥ 4,  3 persons) were available and were obtained from the 
Medical Biobank. These samples had been collected between the time of the first (matched) 
sample collection and the diagnosis date. A total of 570 plasma samples, including the first 
sample, were available for analysis from the AD cases. 
Sampling dates ranged from 12 November 1986 to 2 March 2006, and AD diagnosis dates 
ranged from 1 August 1995 to 10 March 2010. The mean difference in age between cases and 
controls was 0.08 ± 0.81 years, and the mean difference in sampling date was 0.49 ± 53.4 
days. Mean ages of cases and controls at the time of plasma sampling were 61.3 ± 5.6 and 
61.2 ± 5.6 years respectively. Women were older than men in both groups (cases, 62.3 ± 5.3 
vs. 58.1 ± 5.3 years; controls, 62.3 ± 5.3 vs. 57.9 ± 5.2 years; both p < 0.001). For AD cases, 
the mean age at diagnosis was 70.8 ± 6.4 years and the mean interval between plasma 
sampling and diagnosis was 9.4 ± 4.0 (range 0.2 to 20.7) years. 
Plasma A measurements for preclinical AD cases and dementia-free controls are shown in 
Table 1. Results of multiple logistic regressions analyses of the effects of age and sex on free 
A concentrations are presented in Table 2. Among AD cases, greater age was associated 
significantly with higher concentrations of free plasma A42; among controls, women had 
significantly higher concentrations of free A40 than did men. Plasma concentrations of free 
A40 and A42 were correlated significantly among cases and controls (cases: 0.375, p < 
0.001; controls: 0.492, p < 0.001). 
Conditional logistic regression revealed no association between the difference in plasma 
concentrations of free A between cases and controls and AD (Table 1). In addition, sub-
group analyses showed no such association according to sex and age (Table 3). 
No A variable was correlated significantly with the interval between plasma sampling and 
AD diagnosis (Table 4). Analysis of quartiles defined according to this interval also showed 
no significant association with AD (Table 5). 
The analysis of changes in plasma A markers with linear mixed models included two or 
more samples from 150 AD cases. No significant change in markers in the years prior to 
diagnosis was detected (A40: +0.40 units/year, p = 0.317; A42: +0.11 units/year, p = 0.420). 
Discussion 
In this sample of persons with preclinical AD and closely matched dementia-free controls, 
plasma concentrations of free A were not associated with the risk of AD development. 
Among those who developed AD, repeated plasma sampling samples in the years prior to 
diagnosis detected no changes in plasma concentrations of free A. 
The strengths of the present study include the analysis of a large sample of preclinical AD 
cases, identified by cross-referencing of a population-based biobank with subsequent memory 
clinic records, the high clinical diagnostic quality of AD diagnoses, and the use of closely 
matched dementia-free controls. Plasma samples were taken an average 9.4 years before the 
AD diagnosis. 
This study adds further evidence that free plasma A is not a reliable measure of AD risk, and 
thus that it should not be used as an AD biomarker. These findings are in line with previous 
reports of the low predictive value of plasma A [6, 9, 17]. Previous studies have shown a 
low degree of correlation between plasma and CSF concentrations of A [16], and have 
demonstrated that plasma A does not reflect brain A deposition [18]. These results may 
explain the lack of association found in this and other studies. 
One possible explanation for the weak association between plasma concentration of free A 
and AD is that the A peptides measured in plasma primarily represent production of A 
from extra-cerebral cell types. Platelets may be a significant source of plasma A [19], and 
fibroblasts, for example, have been found to produce A upon cytomegalovirus infection 
[20]. 
The current results are limited to the value of plasma concentrations of free A to predict the 
development of AD when measured in a preclinical phase. The results therefore do not 
exclude the possibility that certain fractions of blood or plasma A, or plasma A in 
combination with other markers, could have a predictive value. Furthermore, the results do 
not exclude the possibility that plasma A might have a diagnostic value in symptomatic 
phases of AD. These limitations must be taken into account when interpreting the results. 
 
Conclusion 
Plasma concentrations of free A could not predict the development of clinical AD, and A 
concentrations did not change in the years preceding AD diagnosis in this sample. These 
results indicate that free plasma A is not a useful biomarker for the identification of 
individuals at risk of developing clinical AD. 
Table 1 
Conditional logistic regression of plasma concentrations of free amyloid  and Alzheimer’s 
disease 
Group Alzheimer’s 
disease cases 
Dementia free 
controls 
Odds 
ratio 
95% CI p-value 
pA42, mean ± SD, 
[ng/L] 
43.6 ± 13.1 44.6 ± 12.5 0.994 0.982 –
1.006 
0.316 
pA40, mean ± SD, 
[ng/L] 
142.3 ± 36.3 143.9 ± 41.0 0.999 0.994 –
1.003 
0.525 
pA42:A40 ratio, 
mean ± SD 
0.325 ± 0.131 0.331 ± 0.129 0.664 0.190 –
2.325 
0.522 
Abbreviations: CI, confidence interval; pA, free plasma amyloid  peptide; SD, standard deviation. 
 
Table 2 
Multiple linear regression of plasma concentrations of free amyloid   
 Free plasma  amyloid  1-
42 
 Free plasma amyloid  
1-40 
  p-value  p-value 
Alzheimer’s disease cases      
Age (years) 0.275 0.041  0.341 0.358 
Female sex 0.910 0.605  8.597 0.079 
Dementia free controls      
Age (years) 0.128 0.317  0.357 0.400 
Female sex 3.838 0.023  5.100 0.360 
 
 
Table 3 
Conditional logistic regression of plasma concentrations of free amyloid  and Alzheimer’s 
disease in different subgroups 
Group Alzheimer’s 
disease cases 
Dementia 
free controls 
Odds 
ratio 
95% CI p-value 
Men, n=80 
pA42, mean ± SD, 
[ng/L] 
42.1 ± 14.2 41.3 ± 12.4 1.005 0.981 – 1.029 0.700 
pA40, mean ± SD, 
[ng/L] 
134.6 ± 34.0 138.8 ± 38.5 0.996 0.986 – 1.006 0.396 
pA42:A40 ratio, mean 
± SD 
0.334 ± 0.154 0.312 ± 0.097 3.896 0.291 – 52.199 0.304 
Women, n=259 
pA42, mean ± SD, 
[ng/L] 
44.1 ± 12.7 45.7 ± 12.3 0.990 0.977 –1.004 0.167 
pA40, mean ± SD, 
[ng/L] 
144.6 ± 36.7 145.5 ± 41.7 0.999 0.994 – 1.004 0.774 
pA42:A40 ratio, mean 
± SD 
0.322 ± 0.123 0.337 ± 0.136 0.343 0.075 – 1.571 0.168 
Age < 60 years, n=123 
pA42, mean ± SD, 
[ng/L] 
41.2 ± 13.9 43.8 ± 13.7 0.987 0.969 – 1.005 0.160 
pA40, mean ± SD, 
[ng/L] 
135.5 ± 35.6 140.5 ± 39.5 0.996 0.988 – 1.003 0.253 
pA42:A40 ratio, mean 
± SD 
0.324 ± 0.137 0.333 ± 0.142 0.606 0.095 –3.865 0.596 
Age ≥ 60 years, n=216 
pA42, mean ± SD, 
[ng/L] 
45.0 ± 12.4 45.1 ± 11.7 1.000 0.984 – 1.016 0.962 
pA40, mean ± SD, 
[ng/L] 
146.1 ± 36.2 145.9 ± 41.8 1.000 0.995 –1.006 0.950 
pA42:A40 ratio, mean 
± SD 
0.326 ± 0.127 0.330 ± 0.120 0.719 0.130 –3.958 0.719 
Abbreviations: CI, confidence interval; pA, free plasma amyloid  peptide; SD, standard deviation. 
Table 4 
Correlation between length of time between plasma sampling and diagnosis and plasma 
concentrations of free amyloid   
 Correlation with length of time between 
plasma sampling and diagnosis 
 Correlation  p-value 
Alzheimer’s disease cases    
pA42 -0.027  0.623 
pA40 -0.062  0.256 
pA42:A40 ratio 0.037  0.492 
Dementia free controls    
pA42 -0.061  0.260 
pA40 -0.049  0.370 
pA42:A40 ratio -0.019  0.734 
Abbreviations: pA, free plasma amyloid  peptide. 
 
Table 5 
Conditional logistic regression of plasma concentrations of free amyloid  and Alzheimer’s 
disease, time between sampling and diagnosis in quartiles 
Group Alzheimer’s 
disease cases 
Dementia 
free controls 
Odds 
ratio 
95% CI p-value 
First quartile (78 to 2370 days), n=84 
pA42, mean ± SD, 
[ng/L] 
42.6 ± 12.5 44.5 ± 14.3 0.988 0.964 – 1.012 0.326 
pA40, mean ± SD, 
[ng/L] 
144.2 ± 37.2 141.9 ± 37.6 1.002 0.993 – 1.011 0.662 
pA42:A40 ratio, 
mean ± SD 
0.313 ± 0.131 0.331 ± 0.121 0.309 0.026 – 3.619 0.350 
Second quartile (2371 to 3565 days), n=85 
pA42, mean ± SD, 
[ng/L] 
44.1 ±12.1 46.5 ± 12.6 0.987 0.966 – 1.010 0.263 
pA40, mean ± SD, 
[ng/L] 
144.9 ± 36.9 153.8 ± 48.3 0.994 0.986 – 1.002 0.147 
pA42:A40 ratio, 
mean ± SD 
0.324 ± 0.121 0.328 ± 0.137 0.679 0.040 – 11.459 0.788 
Third quartile (3566 to 4461 days), n=85 
pA42, mean ± SD, 
[ng/L] 
44.5 ± 14.1 45.1 ± 10.1 0.995 0.969 – 1.021 0.702 
pA40, mean ± SD, 
[ng/L] 
140.3 ± 36.6 144.0 ± 32.8 0.996 0.986 –1.006 0.423 
pA42:A40 ratio, 
mean ± SD 
0.330 ± 0.111 0.333 ± 0.141 0.846 0.067 – 10.739 0.897 
Fourth quartile (4462 to 7574 days), n=85 
pA42, mean ± SD, 
[ng/L] 
43.3 ± 13.6 42.3 ± 12.5 1.006 0.983 – 1.030 0.595 
pA40, mean ± SD, 
[ng/L] 
139.6 ± 34.7 136.0 ± 42.3 1.003 0.994 – 1.013 0.472 
pA42:A40 ratio, 
mean ± SD 
0.334 ± 0.156 0.332 ± 0.114 1.085 0.107 – 10.956 0.945 
Abbreviations: CI, confidence interval; pA, free plasma amyloid  peptide; SD, standard deviation. 
 
References 
[1] Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: 
implications for prevention trials. Neuron. 2014;84:608-22. 
[2] Braak H, Del Tredici K. The preclinical phase of the pathological process underlying 
sporadic Alzheimer's disease. Brain. 2015;138:2814-33. 
[3] Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H. Amyloid biomarkers in 
Alzheimer's disease. Trends in pharmacological sciences. 2015;36:297-309. 
[4] Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Alzheimer's Disease Neuroimaging 
I, Minthon L, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying 
early Alzheimer disease. Neurology. 2015;85:1240-9. 
[5] Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. 
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet 
Neurol. 2014;13:614-29. 
[6] Zetterberg H. Plasma amyloid beta-quo vadis? Neurobiol Aging. 2015;36:2671-3. 
[7] Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. Meta-analysis of 
plasma amyloid-beta levels in Alzheimer's disease. J Alzheimers Dis. 2011;26:365-75. 
[8] Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. Plasma amyloid-
beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. 
Archives of neurology. 2012;69:824-31. 
[9] Hansson O, Stomrud E, Vanmechelen E, Ostling S, Gustafson DR, Zetterberg H, et al. 
Evaluation of plasma Abeta as predictor of Alzheimer's disease in older individuals without 
dementia: a population-based study. J Alzheimers Dis. 2012;28:231-8. 
[10] Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, et al. Plasma 
amyloid-beta and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers 
Dement. 2015;11:249-57 e1. 
[11] Boffetta P, Bobak M, Borsch-Supan A, Brenner H, Eriksson S, Grodstein F, et al. The 
Consortium on Health and Ageing: Network of Cohorts in Europe and the United States 
(CHANCES) project--design, population and data harmonization of a large-scale, 
international study. European journal of epidemiology. 2014;29:929-36. 
[12] Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH, et al. 
Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort 
- evaluation of risk factors and their interactions. Scandinavian journal of public health 
Supplement. 2003;61:18-24. 
[13] Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for 
grading the cognitive state of patients for the clinician. Journal of psychiatric research. 
1975;12:189-98. 
[14] American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric 
Association; 2000. 
[15] McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical 
diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the 
auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. 
Neurology. 1984;34:939-44. 
[16] Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, 
et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to 
Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 
2010;31:357-67. 
[17] Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, et al. 
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a 
prospective, population-based cohort study. Archives of neurology. 2008;65:256-63. 
[18] Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not 
reflect brain Abeta levels. Journal of neuropathology and experimental neurology. 
2007;66:264-71. 
[19] Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of 
amyloid beta-peptide in human blood. Biochem Biophys Res Commun. 1995;213:96-103. 
[20] Lurain NS, Hanson BA, Martinson J, Leurgans SE, Landay AL, Bennett DA, et al. 
Virological and immunological characteristics of human cytomegalovirus infection associated 
with Alzheimer disease. J Infect Dis. 2013;208:564-72. 
 
